Ayeramate en es it fr

Ayeramate Brand names, Ayeramate Analogs

Ayeramate Brand Names Mixture

  • No information avaliable

Ayeramate Chemical_Formula


Ayeramate RX_link

No information avaliable

Ayeramate fda sheet

Ayeramate msds (material safety sheet)

Ayeramate Synthesis Reference

No information avaliable

Ayeramate Molecular Weight

309.469 g/mol

Ayeramate Melting Point

< 25 oC

Ayeramate H2O Solubility

Soluble as HCl salt

Ayeramate State


Ayeramate LogP


Ayeramate Dosage Forms

Tablets (oral, 1 mg)

Ayeramate Indication

Used for the symptomatic treatment of parkinsonism.

Ayeramate Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Ayeramate Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Ayeramate side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Ayeramate Patient Information

Ayeramate Organisms Affected

Humans and other mammals